Intellia Therapeutics, Inc. · Biotechnology
NTLAIntellia Therapeutics, Inc.
No earnings date on file for this stock yet.
Lean, stance and evidence on this page are model outputs, not investment advice. Trade at your own risk. Disclaimer →
Intellia Therapeutics earnings preview: what the record says
Across its last 8 reports, NTLA beat the EPS consensus 7 times out of 8 with a figure on file, and the stock moved an average of 6.4% on the first trading day, closing higher 6 of 8 times. That first-day move was larger than the options-implied move in 3 of 8 reports. Measured over five sessions, the average move was 9.2%.
Historically, NTLA has usually stayed inside its implied move. NextPick tracks NTLA in its Cell / Gene Therapy basket alongside CRSP, BEAM, VCEL and PRME, whose prints read through to this one.
Figures come from NextPick's earnings-reaction ledger and the options market. Not investment advice.
NTLA earnings: key questions
How much does NTLA stock move after earnings?
Over its last 8 reports, NTLA moved an average of 6.4% on the first trading day after earnings. The move was larger than the options-implied move in 3 of 8 reports.
Does NTLA usually beat earnings estimates?
NTLA beat the EPS consensus in 7 of its last 8 reports with a surprise on file and missed in 0.